[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Miami\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":581},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,158,0,25,[9,41,62,85,108,136,161,187,209,230,253,276,299,321,342,363,386,406,425,450,468,488,507,531,556],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100054253","phase-2-pembrolizumab-and-lenvatinib-in-mismatch-repair-proficient-recurrent-endometrial-cancer-after-failure-of-first-line-therapy-with-platinum-based-doublet-and-immunotherapy-100054253",false,"NCT07594015","Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy","Phase 2 Open-Label Trial Investigating the Efficacy and Safety of Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Failure of First-Line Therapy With Platinum-based Doublet and Immunotherapy","Inclusion Criteria:\n\n1. Histologically confirmed recurrent endometrial carcinoma, including serous, endometrioid, carcinosarcoma, clear cell subtypes, with measurable disease per RECIST 1.1 criteria.\n2. Mismatch repair (MMR) proficient status confirmed by IHC (Immunohistochemistry) or molecular testing.\n3. Patients must have failed first-line therapy with platinum based doublet with prior immunotherapy.\n4. Patient must have completed next-generation sequencing on either primary or recurrent tumor.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 3.\n6. Age ≥ 18 years.\n7. Female participants must be of non-childbearing potential or for females of child bearing potential (FOCBPs), must agree to use contraception as described in Section 5.6. FOCBPs must not be pregnant or breastfeeding.\n8. At least one measurable lesion according to RECIST 1.1.\n9. Adequate organ function, including:\n\n   * Hemoglobin ≥ 8 g\u002FdL (blood transfusions are permitted)\n   * Absolute neutrophil count ≥ 1000\n   * Platelet count ≥ 100 x 10⁹\u002FL\n   * Glomerular filtration rate (GFR) ≥ 30 mL\u002Fmin\n   * Bilirubin ≤ 1.5 x ULN (upper limit of normal)\n10. Written informed consent obtained from the patient.\n11. At least 3 weeks must have elapsed from any prior therapy\n\nExclusion Criteria:\n\n1. Uterine sarcoma\n2. Active central nervous system metastases or leptomeningeal disease.\n3. History of severe allergic reactions to pembrolizumab, lenvatinib, or any components of the formulations.\n4. Active autoimmune disease requiring chronic systemic steroids for \\> 3 months in the last 6 months prior to enrollment.\n5. Pregnancy or breastfeeding at the time of enrollment.\n6. Previous treatment with lenvatinib or other VEGFR inhibitors.\n7. Concurrent treatment with other investigational drugs or anti-cancer therapies except for adjuvant hormonal therapy for breast cancer.\n8. Uncontrolled concurrent illness, such as active infections that could interfere with study participation.\n9. Blood pressure \\>160 systolic or \\>110 diastolic averaged over last 3 documented measurements.\n10. History of significant cardiovascular events within 12 months prior to enrollment, including myocardial infarction, unstable angina, or congestive heart failure (NYHA Class III or IV).\n11. History of organ transplant or immune suppressive therapy that would interfere with the efficacy or safety of the investigational drugs.\n12. Other malignancies within the past 2 years except for non-melanoma skin cancer.","FEMALE","18 Years",{"count":20,"type":21},46,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The purpose of this study is to determine the efficacy and safety of Pembrolizumab in combination with Lenvatinib in recurrent, mismatch repair-proficient endometrial cancer after failure of first-line therapy with a platinum-based doublet chemotherapy and immunotherapy.",[27],"Recurrent Endometrial Cancer","RECRUITING","2026-07-09",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":21},"2026-09-01",{"date":36,"type":21},"2031-09-01",{"name":38,"class":39},"University of Miami","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":59,"leadSponsor":61,"locationsCount":40},"100053763","phase-3-alternate-pre-med-in-anti-cluster-of-differentiation-20-cd20-pilot-project-100053763","NCT07472413","Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project","Cetirizine Versus Diphenhydramine as a Pre-medication: Tolerability and Safety in Patients With MS Receiving Anti-Cluster of Differentiation 20 (CD20) Infusion Therapy","Inclusion Criteria:\n\n* Ages ≥18 years\n* Able to read and speak in English or Spanish\n* Able to and willing to give informed consent\n* Diagnosis of Multiple Sclerosis (MS)\n* Patients starting or currently receiving ocrelizumab, ublituximab, rituximab\n\nExclusion Criteria:\n\n* Adults unable or unwilling to consent\n* Patients younger than 18 years of age\n* Pregnant women\n* Known hypersensitivity to cetirizine or any of its ingredients or hydroxyzine\n* Moderate or severe renal impairment (creatinine clearance or 11-31 mL\u002Fmin or worse)\n* Patients with prior hypersensitivity reactions on additional preventative measures (e.g. H1 and H2\u002Fproton-pump inhibitor (PPI) the night prior to the infusion due to history of reactions)","ALL",{"count":50,"type":21},60,[52],"PHASE3","The purpose of this study is to assess and compare how well multiple sclerosis (MS) patients tolerate cetirizine versus diphenhydramine as a pre-medication before receiving anti-CD20 infusion therapy of ocrelizumab, ublituximab or rituximab. The study will also compare the safety of cetirizine versus diphenhydramine as a pre-medication for preventing infusion reactions in MS patients receiving anti-CD20 infusion therapy.",[55],"Multiple Sclerosis","NOT_YET_RECRUITING",{"date":31,"type":32},{"date":34,"type":21},{"date":60,"type":21},"2028-07-01",{"name":38,"class":39},{"id":63,"slug":64,"hasResults":12,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":4,"eligibilityCriteria":68,"healthyVolunteers":69,"sex":48,"minAge":18,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100053541","active-versus-passive-sitting-cognition-and-energy-100053541","NCT07699848","Active Versus Passive Sitting, Cognition and Energy","Differences in Muscle Utilization, Tissue Pressure, Cognitive Performance, and Caloric Output Among Active and Passive Sitting Positions.","Inclusion Criteria:\n\n* Adult (18-70)\n\nExclusion Criteria:\n\n* Any current injury in the lower limb or trunk.\n* Use of prescription drugs or supplements that may affect cardiovascular or neuromuscular responses.\n* Reported lack of sleep or stress that may affect physiological responses to exercise.\n* Cardiovascular, respiratory, neurologic, balance, metabolic, or musculoskeletal conditions that could increase risk during exercise testing",true,"70 Years",{"count":72,"type":21},35,[74],"NA","The study will compare cognitive capacity, muscle utilization patterns, soft tissue seated pressure and caloric output during four seated conditions:\n\n1. passive sitting in a regular chair;\n2. passive sitting in an exercise chair;\n3. sitting in the exercise chair during active dynamic exercise; and,\n4. sitting in the chair during active static exercise.",[77,78],"Electromyography","Pressure Injury of Back","2026-07-07",{"date":31,"type":32},{"date":79,"type":32},{"date":83,"type":21},"2027-09-30",{"name":38,"class":39},{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":69,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":40},"100536139","targeted-navigation-in-hepatocellular-carcinoma-hcc-100536139","NCT06260943","Targeted Navigation in Hepatocellular Carcinoma (HCC)","Targeted Navigation to Achieve Health Equity: Increasing Access to Care, Patient Engagement and Research Participation","Inclusion Criteria:\n\n* HCC Patients:\n\n  * Enrolled or eligible for enrollment in Unified Prospective Registry and Biorepository of Patients with Chronic Liver Disease or Hepatobiliary Cancers Including Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma.\n  * Diagnosis of hepatocellular carcinoma, confirmed by clinical chart review and International Classification of Diseases, Tenth Revision (ICD-10) C22.0.\n  * Adults, age 18 or older\n  * Able to provide informed consent\n* All other interviewees:\n\n  * Advocates who will self-identify as having had HCC.\n  * Others who self-identify as either a caregiver or support person of an HCC patient.\n\nPhysicians\u002FLicensed Independent Practitioners, Social Workers, Nurse Navigators, and Research Coordinators will all self-identify as being involved in the care of HCC patients.\n\nExclusion Criteria:\n\n* Unable to speak Spanish or English\n* West Haven Grade 2 or higher hepatic encephalopathy19 or other cognitive impairment.\n* Adults unable or unwilling to consent\n* Individuals who are not yet adults (infants, children, teenagers)\n* Prisoners\n* Given that this study is minimal risk and there are no risks to a potential fetus, investigators will not exclude pregnant women; however, no data about pregnancy or their fetus is being collected",{"count":93,"type":21},210,[74],"The investigators are trying to learn more about the personal perceptions and experiences regarding the needs of patients with liver cancer to help improve the care of all patients. The investigators would like to know whether there are needs that patients have or are aware of, especially those needs that the investigators have not been able to address. The investigators aim to develop a program that helps participants and participant's families to navigate the process of being diagnosed with liver cancer and receiving treatment.",[97,98,99],"Hepatocellular Carcinoma","Cholangiocarcinoma","Hepatobiliary Cancer","2026-06-30",{"date":102,"type":32},"2026-07-02",{"date":104,"type":32},"2024-04-15",{"date":106,"type":21},"2026-10-31",{"name":38,"class":39},{"id":109,"slug":110,"hasResults":12,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":12,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":115,"targetDuration":4,"studyType":22,"phases":117,"briefSummary":118,"conditions":119,"keywords":123,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},"100450216","evaluation-of-grief-therapy-approaches-for-bereaved-parents-100450216","NCT05142605","Evaluation of Grief Therapy Approaches for Bereaved Parents","Meaning-Centered Grief Therapy for Parents Bereaved by Cancer: A Multisite Randomized Controlled Trial","Parent Participant Inclusion Criteria:\n\n* A biological, adoptive, step-parent or legal guardian from across the United States who lost a child diagnosed with cancer as indicated by self-report\n* Age 18 or older as indicated by self-report\n* Experienced the loss of a child diagnosed with cancer at least 6 months prior to enrollment as indicated by medical record or self-report\n* Elevated prolonged grief (PG) symptoms (PG-13-R scores of 30 or above)\n* Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report\n* English-speaking as per the language assessment items below and willing to receive the intervention in English\n* What is the participant's preferred language?\n\n  °(Specify Lang)\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n* How well does the participant speak English?\n\n  * Very well (PARTICIPANT IS ELIGIBLE)\n  * Well (PARTICIPANT is NOT ELIGIBLE)\n  * Not well (PARTICIPANT is NOT ELIGIBLE)\n  * Not at all (PARTICIPANT is NOT ELIGIBLE)\n* Individuals who are pregnant per self-report are eligible to participate\n\nSupport Provider Inclusion Criteria:\n\n* Must be age 18 or over as indicated by self-report\n* Has been identified by the bereaved parent participant as a support or someone important to bereaved parent\n* Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report\n* English-speaking as per the language assessment items below and willing to receive the intervention in English\n* What is the participant's preferred language?\n\n  °(Specify Lang)\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n* How well does the participant speak English?\n\n  * Very well (PARTICIPANT IS ELIGIBLE)\n  * Well (PARTICIPANT is NOT ELIGIBLE)\n  * Not well (PARTICIPANT is NOT ELIGIBLE)\n  * Not at all (PARTICIPANT is NOT ELIGIBLE)\n* Individuals who are pregnant per self-report are eligible to participate.\n\nFamily Participant Inclusion Criteria:\n\n* A biological, adoptive, step-parent or legal guardian from across the United States who lost a child diagnosed with cancer as indicated by self-report\n* Age 18 or older as indicated by self-report\n* Experienced the loss of a child diagnosed with cancer at least 6 months prior to enrollment as indicated by medical record or self-report\n* Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report\n* English-speaking as per the language assessment items below and willing to receive the intervention in English\n* What is the participant's preferred language?\n\n  °(Specify Lang)\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n* How well does the participant speak English?\n\n  * Very well (PARTICIPANT IS ELIGIBLE)\n  * Well (PARTICIPANT is NOT ELIGIBLE)\n  * Not well (PARTICIPANT is NOT ELIGIBLE)\n  * Not at all (PARTICIPANT is NOT ELIGIBLE)\n* Individuals who are pregnant per self-report are eligible to participate.\n\nTraining Case Inclusion Criteria:\n\n* A biological, adoptive, step-parent, or legal guardian from across the United States as indicated by self-report\n* Age 18 or older as indicated by self-report\n* Experienced the loss of a child at least 6 months prior to enrollment as indicated by medical record or self-report\n* Score of 29 or below on the PG-13-R OR lost a child to a cause other than cancer OR child's additional guardian has consented as a Parent Participant and has not provided permission to share participation status OR past participants who indicate an interest in serving as a training case and, in the judgment of the Principal Investigator, would be appropriate to enroll as a training case\n* Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report\n* English-speaking as per the language assessment items below and willing to receive the intervention in English\n* What is the participant's preferred language?\n\n  ° (Specify Lang)\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n* How well does the participant speak English?\n\n  * Very well (PARTICIPANT IS ELIGIBLE)\n  * Well (PARTICIPANT is NOT ELIGIBLE)\n  * Not well (PARTICIPANT is NOT ELIGIBLE)\n  * Not at all (PARTICIPANT is NOT ELIGIBLE)\n* Individuals who are pregnant per self-report are eligible to participate.\n\nTraining Case Support Provider Inclusion Criteria:\n\n* Must be age 18 or over as indicated by self-report\n* Has been identified by the bereaved parent training case participant as a support or someone important to bereaved parent\n* Resides in a state in which a study clinical supervisor is licensed to permit telepsychology practice or otherwise able to comply with current telehealth regulations as indicated by self-report\n* English-speaking as per the language assessment items below and willing to receive the intervention in English\n* What is the participant's preferred language?\n\n  ° (Specify Lang)\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\\_\n* How well does the participant speak English?\n\n  * Very well (PARTICIPANT IS ELIGIBLE)\n  * Well (PARTICIPANT is NOT ELIGIBLE)\n  * Not well (PARTICIPANT is NOT ELIGIBLE)\n  * Not at all (PARTICIPANT is NOT ELIGIBLE)\n* Individuals who are pregnant per self-report are eligible to participate.\n\nParent Participant Exclusion Criteria:\n\n* Significant psychiatric disturbance sufficient, in the investigator\u002Fstudy staff's judgment, to preclude completion of the assessment measures, interview or informed consent\n* Inability to access a functional device for videoconferencing and declines offer to use a study loaner device as indicated by self-report\n* Prisoners\n* Participants unable to consent\n\nSupport Provider Exclusion Criteria:\n\n* Significant psychiatric disturbance sufficient, in the investigator\u002Fstudy staff's judgment, to preclude informed consent\n* Inability to access a computer with Internet as indicated by self-report\n* Prisoners\n* Participants unable to consent\n\nFamily Participant Exclusion Criteria:\n\n* Significant psychiatric disturbance sufficient, in the investigator\u002Fstudy staff's judgment, to preclude informed consent\n* Inability to access a computer with Internet as indicated by self-report\n* Prisoners\n* Participants unable to consent\n\nTraining Case Exclusion Criteria:\n\n* Significant psychiatric disturbance sufficient, in the investigator\u002Fstudy staff's judgment, to preclude completion of the assessment measures, interview or informed consent\n* Inability to access a functional device for videoconferencing and declines offer to use a study loaner device as indicated by self-report\n* Prisoners\n* Participants unable to consent\n\nTraining Case Support Provider Exclusion Criteria\n\n* Significant psychiatric disturbance sufficient, in the investigator\u002Fstudy staff's judgment, to preclude informed consent\n* Inability to access a computer with Internet as indicated by self-report\n* Prisoners\n* Participants unable to consent",{"count":116,"type":21},415,[74],"The purpose of this study is to compare three types of support programs for parents who have lost a child. The study will see how these support programs affect participants' grief and depression symptoms. The three support programs are called Meaning-Centered Grief Therapy, Supportive Counseling, and Enhanced Usual Care.",[120,121,122],"Grief","Bereavement","Cancer",[124,125,126],"Parental bereavement","Parents","Elevated prolonged grief symptoms","2026-06-29",{"date":129,"type":32},"2026-07-01",{"date":131,"type":32},"2022-03-31",{"date":133,"type":21},"2027-05-31",{"name":38,"class":39},5,{"id":137,"slug":138,"hasResults":12,"nctId":139,"briefTitle":140,"officialTitle":141,"acronym":4,"eligibilityCriteria":142,"healthyVolunteers":12,"sex":48,"minAge":143,"maxAge":144,"enrollmentInfo":145,"targetDuration":4,"studyType":22,"phases":147,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":40},"100635745","play2control-study-100635745","NCT07556679","PLAY2CONTROL Study","Active Video Games and Their Effect on Weight Loss and HgbA1c in Patients With Obesity and Type 2 Diabetes Mellitus","Inclusion Criteria:\n\n* Patients followed at the University of Miami Pediatric Endocrinology Clinic\n* Must have a diagnosis of Obesity (BMI \\>= 95th percentile) and Type 2 Diabetes Mellitus (Hemoglobin A1c \\> 6.5%)\n* Children and teenagers, 5-18 years old\n* Young adults 19-21 years old\n\nExclusion Criteria:\n\n* Patients who have conditions preventing physical activity (such as physical limitations)\n* Patients without Televisions at home\n* Pregnant females\n* Patients in juvenile detention or prison\n* Adults unable to consent","5 Years","21 Years",{"count":146,"type":21},30,[74],"The purpose of this study is to assess the impact of active video gaming participation in otherwise sedentary patients with obesity and Type 2 diabetes mellitus. The study will assess changes in sedentary time, activity level and changes in weight and Hemoglobin A1c, as well as other complications related to obesity that is monitored in clinic.",[150,151],"Type 2 Diabetes","Obesity & Overweight",[153],"Pediatrics","2026-06-26",{"date":129,"type":32},{"date":157,"type":21},"2026-08",{"date":159,"type":21},"2027-08",{"name":38,"class":39},{"id":162,"slug":163,"hasResults":12,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":12,"sex":48,"minAge":18,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":172,"conditions":173,"keywords":175,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":40},"100638275","self-applied-tavns-for-cipn-100638275","NCT07596030","Self-applied taVNS for CIPN","Feasibility of Self-Applied Vagus Nerve Stimulation for Chemotherapy Induced Peripheral Neuropathy","Inclusion Criteria:\n\nChemotherapy-induced peripheral neuropathy (CIPN) group:\n\n* Age 18-80 years\n* Prior exposure to platinum or taxane chemotherapy\n* Glove\u002Fstocking dysesthesias ≥3 months that began after neurotoxic chemotherapy\n* Worst CIPN-related pain ≥4\u002F10 over the last week\n\nRegistry Cohort:\n\n* Age 18-80 years\n* Prior exposure to platinum or taxane chemotherapy\n* Denis any current neuropathic symptoms as described above.\n\nExclusion Criteria:\n\nAll participants:\n\n* Unstable cardiac disease\u002F Known arrhythmias\n* Head or neck cancer or metastases\n* Recent ear trauma or active dermatologic disease at the stimulation site\n* \\\u003C2 months since completion of cancer treatment or surgery\n* Metal implants in the head or neck (e.g., cochlear implant)\n* Implanted electronic devices (e.g., pacemaker)\n* Known allergy to tape\u002Fadhesives\n* History of seizure\u002Fepilepsy, intracranial pathology, or skull defect\n* Pregnancy","80 Years",{"count":170,"type":21},36,[74],"The purpose of this study is to determine the feasibility of using a portable device at home to self-administer transcutaneous auricular vagus nerve stimulation (taVNS). This handheld device has two small electrodes that are placed on specific areas of the outer ear. This device delivers a mild electrical stimulation to the vagus nerve through the ear. This study will explore how taVNS may affect symptoms of chemotherapy-induced peripheral neuropathy (CIPN). Participants will be assigned to one of two cohorts based on the presence of chemotherapy-induced peripheral neuropathy (CIPN). Participants with CIPN will be placed in the intervention cohort (n=24) and will complete a 2-week trial of daily self-applied taVNS. Participants without CIPN will be placed in the registry cohort (n=12) and will complete study measurements without receiving the intervention. The registry cohort will not receive the taVNS intervention but will undergo identical physiological assessments at baseline and at a 2 week follow up to control for testing effects and biological variability.",[174],"Chemotherapy Induced Peripheral Neuropathy",[176,177,178,179],"vagus nerve stimulation","peripheral neuropathy","heart rate variability","transcranial magnetic stimulation","2026-06-25",{"date":154,"type":32},{"date":183,"type":32},"2026-06-02",{"date":185,"type":21},"2027-07",{"name":38,"class":39},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":191,"acronym":4,"eligibilityCriteria":192,"healthyVolunteers":12,"sex":48,"minAge":18,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":22,"phases":196,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":203,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":40},"100474101","the-neural-underpinnings-of-depression-and-cannabis-use-in-young-people-living-with-hiv-100474101","NCT05453513","The Neural Underpinnings of Depression and Cannabis Use in Young People Living With HIV","Inclusion Criteria:\n\n* HIV seropositivity confirmed with lab report, medical records, or HIV testing.\n* Between the ages of 18-39 years\n* Fluency in English or Spanish\n* Ability to provide informed consent and perform study procedures, including estimated full-scale intelligence quotient (IQ) \\>75 to ensure that participants are able to understand the study.\n* Cannabis users: To capture a wide range of cannabis use frequency, meeting Diagnostic and Statistical Manual 5 (DSM-5) criteria for Cannabis use Disorder (CUD) will not be required. However, in order to ensure sufficient exposure, cannabis use will be significant (self-reported use on ≥20 of the prior 30 days and positive THC urine toxicology).\n* Depressed: In order to capture a wide range of depression illness severity, we will allow participants with subthreshold depression, defined as a raw severity score of ≥12 on the Montgomery Asberg Depression Rating Scale (MADRS).\n\nExclusion Criteria:\n\n* Perinatally acquired HIV infection, as early neurodevelopmental alterations and HIV legacy effects may exist in this group\n* Pregnancy or lactation\n* Current Substance Use Disorder other than cannabis or nicotine\n* Certified for or self-reported medical cannabis use, or intent to become certified\n* Current cocaine use by self-report or urine toxicology\n* central nervous system (CNS) disease or injury, or neuro-degenerative disease\n* Unique pain syndromes (e.g. multiple sclerosis, rheumatoid arthritis);\n* Severe medical illness such as end-stage renal disease, heart failure, cirrhosis, or cancer\n* MRI contraindication such as claustrophobia, metallic ink tattoos, or pacemaker.\n\nDepressed cannabis non-users:\n\n* At baseline, all participants will be psychotropic-medication-free for ≥1 month prior to study enrollment (or ≥3 months for medications with longer half-lives). Benzodiazepines and sleeping aids taken on an as-needed basis will be allowed, however we will require a 4-day abstinence period before the scan.\n* Exclusionary are participants with a DSM-5 diagnoses of bipolar disorder, psychotic disorders, autism spectrum disorders, and all non-cannabis substance-related disorders will be exclusionary. disorder (PTSD) are not uncommon among depressed individuals and will be\n* Anxiety disorders, obsessive-compulsive disorder (OCD), and post-traumatic stress are allowed as long as depressive symptoms are primary.\n\natypical of depression. • Suicidal ideations (SI) without a specific plan (defined as passive SI) are common in depression and will be allowed. However, if SI constitutes an imminent risk to self or others (defined as active SI), the participant will be withdrawn from the study and emergency procedures will be initiated immediately, including ER admission.\n\nDepressed cannabis users:\n\n• Exclusion criteria will be the same as depressed cannabis non-users except for cannabis use.\n\nNon-depressed cannabis users:\n\n• Will have no major psychiatric conditions other than cannabis use\u002Fdisorder.\n\nNon-depressed cannabis non-users:\n\n• Exclusion criteria will be the same as for non-depressed cannabis users; in addition participants will not report cannabis use in the prior 90 days and have a urine toxicology test negative for cannabis.","59 Years",{"count":195,"type":21},280,[74],"To elucidate mechanisms of substance use disorders (SUD) and comorbid mental illnesses in people living with HIV (PLWH), the study team seeks to investigate reward and pain circuitry in cannabis use and depression comorbidity, two highly prevalent conditions in PLWH. The study team proposes a tightly integrative study to test the overall hypothesis that cannabis use and depression in young PLWH have an additive effect, inducing both reward deficits and pain hypersensitivity, and that this pattern will predict worse outcomes at 1 year follow-up.",[199,200,201],"Depression","Cannabis Use Disorder","HIV","2026-06-24",{"date":127,"type":32},{"date":205,"type":32},"2022-04-01",{"date":207,"type":21},"2027-07-30",{"name":38,"class":39},{"id":210,"slug":211,"hasResults":12,"nctId":212,"briefTitle":213,"officialTitle":213,"acronym":214,"eligibilityCriteria":215,"healthyVolunteers":12,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":216,"targetDuration":4,"studyType":22,"phases":218,"briefSummary":219,"conditions":220,"keywords":222,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":202,"lastUpdatePostDateStruct":225,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":229,"locationsCount":40},"100413404","integrated-navigation-services-for-treatment-adherence-counseling-and-research-100413404","NCT04663152","Integrated Navigation Services for Treatment Adherence, Counseling, and Research","INSTACARE","Inclusion Criteria:\n\n* Ages 18 years or older\n* Miami-Dade Resident at time of enrollment\n* self-identify as Black\n* Viral load \\> 200 mL within the last 6-months (VL must be verified via electronic medical record or lab report prior to enrollment)\n\nExclusion Criteria:\n\n* Any other condition(s) that the treating clinician determines would limit participant from meaningful study participation.",{"count":217,"type":21},10,[74],"The goal of this research is to determine whether a Community Health Worker (CHW) intervention including a mobile telehealth (M-Health) component can help achieve long term viral suppression among Black people with poorly controlled HIV.",[221],"HIV Infection Primary",[223,224],"HIV viral suppression","community health worker",{"date":127,"type":32},{"date":227,"type":32},"2023-07-26",{"date":133,"type":21},{"name":38,"class":39},{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":48,"minAge":237,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":22,"phases":241,"briefSummary":242,"conditions":243,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":250,"leadSponsor":252,"locationsCount":40},"100644522","tailored-anti-inflammatory-american-diet-for-patients-with-crohns-disease-100644522","NCT07671872","Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease","Targeting Gut Inflammation Through Diet: a Tailored American Diet for Patients With Crohn's Disease","Inclusion Criteria:\n\n* Documented diagnosis with Crohn's Disease from medical records.\n* Ages 16-75\n* Mild to moderately active CD disease, defined by one of the following criteria:\n\nCrohn's disease activity index (CDAI) 150-250 (mild-to-moderate only active disease) AND presence of active inflammation either by: fecal calprotectin \\>150mg\u002Fdl. or radiologic findings of active ileal and\u002For colonic disease, or endoscopic findings showing active ileal and\u002For colonic disease within 4 weeks of baseline\n\n-On stable medications for their disease as or 3 months if medication is not listed\n\nExclusion Criteria:\n\n* Diagnosis of Ulcerative Colitis (UC).\n* Prior J pouch or diversion\n* Recent inflammatory bowel disease (IBD) related hospitalizations in the last 4 weeks\n* Clostridium difficile or enteric infections in the last 4 weeks\n* Use of probiotics in the last 4 weeks\n* Patients following the specific carbohydrate diet or Mediterranean diet or anti-inflammatory diet\n* Active cancer or conditions limiting their ability to follow a diet (heart failure, end stage renal disease)\n* Pregnancy, breastfeeding or planning to become pregnant during study period\n* Use of Total Parenteral Nutrition at the time of screening and during the study period\n* Other significant or life-threatening co-morbidities\n* The need for antibiotic use during the study period\n* Adults unable to consent\n* Ages \\\u003C 16 and \\> 75 years old\n* Prisoners\n* Crohn's specific complicated disease including active Stenotic (stricturing, B2) disease within the past 12 months, or Internal penetrating (B3) disease, or Draining perianal fistula, or Prior bowel resection\n* Patients with concomitant Celiac disease","16 Years","75 Years",{"count":240,"type":21},122,[74],"The purpose of this study is to test the effect of an anti-inflammatory diet tailored for patients living in the United States with Crohn's Disease (CD) on clinical symptoms and disease inflammation and to identify biomarkers of response to dietary therapy.",[244,245,246],"Crohn's Disease, Active","Crohn's Disease (CD)","Diet Interventions","2026-06-22",{"date":154,"type":32},{"date":157,"type":21},{"date":251,"type":21},"2030-08",{"name":38,"class":39},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":22,"phases":261,"briefSummary":262,"conditions":263,"keywords":266,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":269,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":275},"100595431","implementing-depression-and-adherence-treatment-100595431","NCT07032363","Implementing Depression and Adherence Treatment","Implementing Depression and Adherence Treatment in South Africa HIV Care","Inclusion Criteria for Clinics (the primary \"participants\"):\n\n* Clinics are eligible if they provide HIV primary care via the City of Cape Town (CoCT) Department of Health\n* Clinics will be assigned to the study upon notice of funding and before start up.\n\nInclusion Criteria for Patient-level Outcomes:\n\nAlthough the unit of randomization is at the clinic level, the study will be looking at adult patient level data at each clinic. All patients engaged in care at one of the 10 primary care\u002FHIV treatment clinics in the study will be included if they:\n\n* Are 18 years of age or older and\n* Have a detectable HIV viral load (operationalized as the lower limit of detection on the standard test is used at the local clinic), or presumed detectable viral load per clinic standards\n* Screen in for depression via the PHQ (following detection standards set in clinics)\n\nExclusion Criteria:\n\n-Children below the age of 18 will not be included in the proposed study for adults.",{"count":217,"type":21},[74],"The goal of this clinical trial is to compare a core set and enhanced set of implementation strategies in increasing the reach of evidence-based treatments to patients with HIV and depression. The main questions it aims to answer are:\n\nWhat proportion of patients start an evidence-based treatment for depression (reach)? What percentage of patients show clinical improvement in depression and what percentage attain viral undetectability within one year (effectiveness)?\n\nResearchers will compare high and low reach clinics to further inform tailored implementation strategies for uptake and maintenance.\n\nClinics will be randomized into one of two study arms: core versus enhanced strategies. In both arms, core strategies will be utilized. Enhanced clinics will also receive more resource-intensive training.",[199,201,264,265],"Adherence, Treatment","AIDS",[267,201,268],"implementation science","depression",{"date":202,"type":32},{"date":271,"type":32},"2026-05-20",{"date":273,"type":21},"2030-05",{"name":38,"class":39},3,{"id":277,"slug":278,"hasResults":12,"nctId":279,"briefTitle":280,"officialTitle":281,"acronym":282,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":22,"phases":286,"briefSummary":288,"conditions":289,"keywords":291,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":293,"startDateStruct":294,"completionDateStruct":296,"leadSponsor":298,"locationsCount":40},"100548980","phase-1-starlite-for-unresectable-high-grade-gliomas-100548980","NCT06428045","STARLITE for Unresectable High-Grade Gliomas","Synergistic Treatment With Antiretrovirals and Laser Interstitial Thermal thErapy (STARLITE) for Unresectable High-Grade Gliomas: A Phase 1 Study","STARLITE","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Patients with a histologically confirmed or suspected high-grade glioma (HGG) by MRI.\n\n   a. For cases with suspected HGG, intraoperative frozen section diagnoses of HGG must be made by pathologists (Section 4.4.1).\n3. Uni-focal or butterfly gliomas that can receive ≥70% of lesion volume ablated as determined by the treating surgeon.\n4. Gliomas must be located or positioned where surgical resection is either not feasible or high-risk as deemed by a group of surgical neuro-oncologists.\n5. Preoperative Karnofsky score ≥ 70 (APPENDIX A).\n6. Patients must have demonstrable normal organ function as defined below within 14 days of surgery.\n\n   1. Absolute neutrophil count (ANC) ≥ 1500 cells\u002Fmm3\n   2. Platelets ≥ 100,000 cells\u002Fmm3\n   3. Hemoglobin ≥ 9.0 g\u002FdL. Use of transfusion or other intervention to achieve this hemoglobin level is acceptable.\n   4. Blood urea nitrogen (BUN) ≤ 35 mg\u002FdL and creatinine ≤ 1.9 mg\u002FdL and estimated glomerular filtration rate (eGFR) or creatinine clearance rate \\> 50 mL per minute.\n   5. Electrocardiogram (ECG) without evidence of acute cardiac ischemia.\n   6. Prothrombin time (PT)\u002FInternational Normalized Ratio (INR) \\\u003C1.4\n   7. Liver function tests: Aspartate aminotransferase (AST) and alanine transaminase (ALT) at or below 2.5 times the upper limit of normal (ULN).\n   8. Sodium level \\> 130 mg\u002FL. Use of salt resection or hypertonic saline to achieve this sodium level is acceptable.\n7. Patients must be able to understand and sign informed consent.\n\nExclusion Criteria:\n\n1. Patients with human leukocyte antigen (HLA) HLA-B\\*5701 hypersensitivity (Section 10.1.6.7).\n2. Patients with sensitivity to abacavir, lamivudine, or ritonavir (Section 7.3.1).\n3. Patients with a previous history of HIV infection.\n4. Patients with uncontrolled hepatitis B or C infection.\n5. Patients who have received any surgical resection for this tumor.\n\n   a. Patients who have received an open biopsy for this disease are still eligible for participation.\n6. Patients who have received chemotherapy or radiation for this disease.\n7. Patients who are taking dofetilide (Section 4.10.1).\n8. Patients on a regimen of 1 or more prohibited medications as described in Section 4.10.1 that cannot be discontinued or switched to a more compatible medication. For more information on prohibited and precautionary use medications for patients on this study, please see Section 4.10.\n9. Patients not eligible to obtain MRI with and without contrast.\n10. Recurrent HGG.\n11. Presence of current infection, such as sepsis, meningitis, bacteremia, or pneumonia.\n12. Fever within 48 hours of surgery (Temperature\\> 38.0°C).\n13. Severe co-morbidity that would confer excess risk of surgery, radiation, or chemotherapy, as determined by the treating physician.\n14. Any co-morbidity or psychiatric ailment that in the Investigator's opinion will prevent administration or completion of protocol therapy.\n15. Pregnant women.\n16. Patients must be willing to use contraception as described in Section 4.11.\n17. Patients receiving other investigational agents or concurrent enrollment in another therapeutic clinical trial.\n18. Prisoners.\n19. Adults unable to consent.",{"count":285,"type":21},24,[287],"PHASE1","The purpose of this study is to determine whether newly diagnosed high-grade glioma(s) that cannot be removed surgically change as a result of the study treatment; and to identify and evaluate the potential side effects (good and bad) of the study treatment in patients with newly diagnosed high-grade glioma(s) that cannot be removed surgically.",[290],"High Grade Glioma",[292],"Unresectable High Grade Glioma",{"date":180,"type":32},{"date":295,"type":32},"2025-04-15",{"date":297,"type":21},"2030-04-30",{"name":38,"class":39},{"id":300,"slug":301,"hasResults":12,"nctId":302,"briefTitle":303,"officialTitle":304,"acronym":4,"eligibilityCriteria":305,"healthyVolunteers":69,"sex":17,"minAge":306,"maxAge":168,"enrollmentInfo":307,"targetDuration":4,"studyType":22,"phases":308,"briefSummary":309,"conditions":310,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":314,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":40},"100617146","womens-healthy-aging-and-menopause-wham-100617146","NCT07314827","Women's Healthy Aging and Menopause; (WHAM)","A Feasibility Study Examining the Comparison of Transcendental Meditation Versus Health Education on Psychological and Hemodynamic Function in Post-menopausal Women","Inclusion Criteria:\n\n1. ≥130 systolic blood pressure (SBP) ≤160 and\u002For 84 ≥ diastolic blood pressure (DBP) ≤100.\n2. Perceived stress scale (PSS-4) \\> 5\n3. Able to give informed consent.\n4. Understand study procedures and comply with them for the length of the study.\n5. Ages between 50 and 80 years.\n6. Post-menopausal ≥ 1 year since last menstruation\n7. Reads and speaks English\n8. UHealth patients\n9. Working at least part-time\n\nExclusion Criteria:\n\n1. Currently in a meditation program.\n2. Meditates more than once per week\n3. Recent stroke or cerebral neurologic impairment.\n4. Current uses of mood stabilizers or antipsychotics.\n5. Has been diagnosed with bipolar disorder, schizophrenia, or substance use disorder.\n6. Inability to give written informed consent in English.","50 Years",{"count":50,"type":21},[74],"The present study will examine whether women at high risk for developing hypertension, i.e., post-menopausal status, at least mild psychological distress, and mildly elevated blood pressure, show improvements in these risk factors after a 12-week Transcendental Meditation (TM) intervention compared to Women's Health Education (WHE). Positive findings will provide initial evidence of using nonpharmacological methods, such as TM, to prevent hypertension in postmenopausal women.",[311,312],"Meditation","Health Education","2026-06-18",{"date":315,"type":32},"2026-06-23",{"date":317,"type":21},"2026-10-01",{"date":319,"type":21},"2028-01-31",{"name":38,"class":39},{"id":322,"slug":323,"hasResults":12,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":48,"minAge":328,"maxAge":4,"enrollmentInfo":329,"targetDuration":4,"studyType":22,"phases":331,"briefSummary":332,"conditions":333,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":336,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":275},"100567095","phase-2-axatilimab-in-combination-with-extracorporeal-photopheresis-ecp-in-chronic-graft-versus-host-disease-100567095","NCT06663722","Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease","A Phase II b Study of Axatilimab in Combination With Extracorporeal Photopheresis (ECP) in Chronic Graft-versus-Host Disease","Inclusion Criteria:\n\n1. Recipient of allogeneic hematopoietic cell transplantation (HCT).\n2. Age greater or equal to 12.\n3. Chronic GVHD per 2014 National Institutes of Health Consensus Criteria (NCC) (Jagasia et al. 2015) or overlap syndrome requiring new therapy in patients with at least 2 prior lines of therapy, steroid refractoriness, or steroid dependence:\n\n   1. Prior systemic lines of therapy may include corticosteroids, calcineurin inhibitor (CNI) or sirolimus, or other systemic immunosuppressive agent such as ruxolitinib, belumosudil, or ibrutinib. GVHD prophylaxis does not count as a prior line of therapy.\n   2. Steroid refractory is defined as any of the following criteria:\n\n      * i. Manifestations progress despite the use of ≥ 1 mg\u002Fkg\u002Fday prednisone for at least 1 week\n      * ii. Manifestations persist without improvement despite treatment with ≥ 0.5 mg\u002Fkg\u002Fday or 1 mg\u002Fkg every other day for at least four weeks.\n      * iii. Recurrence after a CR, or\n      * iv. Progression after a PR.\n   3. Steroid dependence is defined as inability to control cGVHD symptoms while tapering prednisone below 0.25 mg\u002Fkg\u002Fday on at least two occasions separated by at least 8 weeks. There must be evidence of clinically active cGVHD.\n4. For patients receiving approved or commonly used agents, all GVHD systemic treatments should be discontinued except for corticosteroids and drugs being continued from GVHD prophylaxis at screening.\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0-3 as assessed at Screening.\n6. Platelet count \\> 50,000 platelets\u002FμL and absolute neutrophil count \\> 1,000 cells\u002FμL as measured at Screening.\n7. Aspartate aminotransferase (AST), alanine aminotransferase (ALT) ≤ 2.5 x upper limit of normal (ULN), unless attributed to presumed cGVHD as measured at Screening.\n8. Stable dose of corticosteroids for at least 14 days prior to treatment.\n9. Sexually mature individuals must use contraception as described in Section 4.12. For individuals less than 18 years of age, sexual maturity will be determined as per treating pediatrician.\n\nExclusion Criteria:\n\n1. Pregnancy or breast-feeding.\n2. Active relapse of underlying malignancy.\n3. History or the presence of interstitial pneumonitis or drug-related pneumonitis.\n4. Active gastrointestinal (GI) bleeding.\n5. Inability to tolerate volume shifts associated with ECP (e.g., inadequate renal, hepatic, pulmonary and cardiac function (ejection fraction (EF) \\\u003C 40%) per Investigator discretion.\n6. History of myositis.\n7. History of splenectomy.\n8. History of pancreatitis.\n9. History of other malignancy (within 3 years of Screening) unless treated with curative intent and approved by Principal Investigator (PI).\n10. Significant, uncontrolled, or active comorbid conditions or are unable to adhere to the study requirements.\n11. Acquired Immune Deficiency Syndrome (AIDS) or active hepatitis B (Hep B) or active hepatitis C (Hep C) infection.\n12. Prior colony-stimulating factor-1 (CSF-1R) targeted therapies.\n13. Prior history of ECP treatment failure or intolerance.\n14. Intolerance to methoxsalen, heparin, or citrate products.\n15. Patients with aphakia due to risk of increased retinal damage or photosensitive disease (albinism, systemic lupus erythematosus, porphyria).\n16. Lack of stable IV access. Acceptable forms include central venous catheter, peripherally inserted central catheter (PICC), or peripheral IV line per institutional guidelines.\n17. Insurance denial of coverage for the ECP procedure.","12 Years",{"count":330,"type":21},49,[24],"The purpose of this study is to see whether giving participants a combination treatment of Axatilimab and Extracorporeal Photopheresis (ECP) is effective against chronic Graft-versus-Host Disease (cGVHD).",[334,335],"Chronic Graft Versus Host Disease","cGVHD",{"date":247,"type":32},{"date":338,"type":32},"2025-05-05",{"date":340,"type":21},"2030-05-05",{"name":38,"class":39},{"id":343,"slug":344,"hasResults":12,"nctId":345,"briefTitle":346,"officialTitle":347,"acronym":4,"eligibilityCriteria":348,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":353,"conditions":354,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":313,"lastUpdatePostDateStruct":356,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":362},"100547757","phase-4-study-evaluating-safety-tolerability-and-metabolism-of-niraparib-100547757","NCT06412120","Study Evaluating Safety, Tolerability, and Metabolism of Niraparib","Single-Arm, Prospective, Multicenter Study Evaluating Safety, Tolerability, and Metabolism of Niraparib as Maintenance Following Front-Line Treatment for Ovarian Cancer in Women of African Ancestry","Inclusion Criteria:\n\n1. Participant must be female ≥18 years of age, able to understand study procedures, and agree to participate in the study by providing written informed consent.\n2. Self-identify as Black. Please note that individuals who identify as Latino are eligible to participate so long as they also self-identify as Black.\n3. Participant has completed adjuvant treatment for newly diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer according to the International Federation of Gynecology and Obstetrics staging criteria.\n4. Participant must have high-grade serous or high-grade endometrioid histology.\n5. Participant must provide saliva and\u002For blood specimens for assessment of germline mutation(s) in the Fanconi Anemia pathway.\n6. Participant must provide formalin-fixed, paraffin-embedded (FFPE) or fresh tumor specimen from initial cytoreductive surgery (primary debulking) or initial pre-treatment core biopsy (if neoadjuvant chemotherapy (NACT) received; tumor obtained from interval cytoreduction acceptable if pre-treatment biopsy not obtained).\n7. Participant must have had a complete or partial clinical response to adjuvant treatment as confirmed by CT scan within 8 weeks after completion of the last dose of platinum-based chemotherapy.\n8. Participant must have recovered to ≤ Grade 1 in terms of toxicity from prior treatments.\n9. Participant must not have any known contraindication or hypersensitivity to niraparib or any of its excipients.\n10. Participants must be considered candidates for maintenance niraparib therapy by their treating physician.\n11. Participants should have adequate organ function as defined below:\n\n    * Platelets ≥ 100 platelets × 10\\^9\u002FL\n    * Hemoglobin ≥ 9 g\u002FdL or 5.6 mmol\u002FL\n    * Aspartate transaminase (AST) and alanine transaminase (ALT) ≤2.5 × upper limit of normal (ULN), \\\u003C5× in patients with known liver metastases\n    * Serum total bilirubin ≤ 1.5 × ULN\n    * 1.5-3.0 × ULN may be included with appropriate starting dose adjustment to 200 mg daily.\n    * Creatinine \\\u003C1.5 × ULN or estimated glomerular filtration rate (eGFR) ≥50 mL\u002Fmin by Cockcroft-Gault\n\n      * Depending on scenario, glomerular filtration rate (GFR) 30-49 mL\u002Fmin can be permissible.\n12. Patients with known human immunodeficiency virus (HIV) are allowed if they meet all the following criteria:\n\n    * Cluster of differentiation 4 (CD4) ≥350\u002FμL and viral load \\\u003C400 copies\u002FmL\n    * No history of acquired immunodeficiency syndrome (AIDS)-defining opportunistic infections within 12 months before enrollment\n    * No history of HIV-associated malignancy for the past 5 years. Concurrent antiretroviral therapy as per the most current National Institutes of Health (NIH) Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV started \\>4 weeks before study enrollment.\n13. A female participant is eligible to participate if she is not pregnant or breastfeeding and at least one of the following conditions applies:\n\n    * Is not a woman of childbearing potential (WOCBP), or\n    * Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of \\\u003C1% per year) from the Screening Visit through at least 180 days after the last dose of study treatment and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The Investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study treatment, and\n    * A WOCBP must have a negative test result from a highly sensitive pregnancy test (urine or serum, as required by local regulations) within 72 hours before treatment. Additional periodic testing should be carried out according to the protocol.\n\n    Note: The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy.\n14. Participant must agree to complete HRQoL and patient reported outcomes (PRO) measures throughout the study period.\n\nExclusion Criteria:\n\n1. Any of the following histologies: low-grade serous carcinoma, grade 1 or 2 endometrioid adenocarcinoma, clear cell, mucinous, transitional cell, carcinosarcoma, undifferentiated, dedifferentiated\n2. Any known history or current diagnosis of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)\n3. Primary progressive, platinum-refractory disease\n4. Participant is at an increased risk of bleeding due to concurrent conditions (eg, major injuries or major surgery within the past 28 days before start of study treatment).\n5. Current diagnosis of platelet disorder (eg, thrombotic thrombocytopenic purpura (TTP), immune thrombocytopenia (ITP))\n6. Inability to swallow orally administered medication or has a gastrointestinal disorder likely to interfere with absorption of the study medication\n7. Participants that have systolic blood pressure (SBP\\])\\>140 mmHg or diastolic blood pressure (DBP)\\>90 mmHg that has not been adequately treated or controlled.\n8. Active second primary malignancy\n9. Participant is pregnant, currently breastfeeding an infant, or expecting to conceive children while receiving study treatment and\u002For for up to 180 days after the last dose of study treatment.\n10. Participant has received a live vaccine within 30 days of planned start of study therapy. Coronavirus disease 2019 (COVID-19) vaccines that do not contain live viruses are allowed.\n11. Participant has received a transfusion (platelets or red blood cells) or colony-stimulating factors (eg, granulocyte macrophage colony-stimulating factor or recombinant erythropoietin) within 4 weeks before the first dose of study treatment.\n12. Participant has had radiotherapy encompassing \\>20% of the bone marrow within 2 weeks or any radiation therapy within 1 week before Day 1 of protocol therapy.\n13. Participant has leptomeningeal disease, carcinomatous meningitis, symptomatic brain metastasis, or radiographic signs of central nervous system hemorrhage.\n14. Participant has current active pneumonitis or any history of pneumonitis requiring steroids (any dose) or immunomodulatory treatment within 90 days of planned start of the study.\n15. Participants with active hepatitis B or C infection.\n16. Patient with prior history of posterior reversible encephalopathy syndrome (PRES).\n17. Patients with impaired decision-making capacity.\n18. Participants have high medical risk due to a serious, uncontrolled medical disorder; non malignant systemic disease; or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, active uncontrolled coagulopathy, bleeding disorder, or any psychiatric disorder that prohibits obtaining informed consent.\n19. Patient is currently receiving one or more cytotoxic, hormonal, or other medications to treat their cancer.",{"count":350,"type":21},70,[352],"PHASE4","The purpose of this study is to identify the genetic characteristic(s), specifically degree of African ancestry, and environmental characteristic(s) that appear to be related to the effects, both good and bad, that the maintenance treatment has women with ovarian cancer. In this study, an investigational medication called niraparib is being tested for the treatment of ovarian cancer. Niraparib works by blocking the ability of cancer cells to fix their genes. Cancer cells with damaged genes have a harder time growing and spreading in the body and can even die.",[355],"Ovarian Cancer",{"date":315,"type":32},{"date":358,"type":32},"2026-06-08",{"date":360,"type":21},"2031-06-08",{"name":38,"class":39},4,{"id":364,"slug":365,"hasResults":12,"nctId":366,"briefTitle":367,"officialTitle":368,"acronym":4,"eligibilityCriteria":369,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":370,"targetDuration":4,"studyType":22,"phases":372,"briefSummary":373,"conditions":374,"keywords":376,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":380,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":40},"100644146","bridges-an-hiv-doula-program-100644146","NCT07664423","BRIDGES: An HIV Doula Program","BRIDGES: A Patient-Centered, Community-Informed HIV Doula Program That Supports Infant Feeding Choice","Inclusion Criteria:\n\n* Pregnant and postnatal women, followed at the institutional clinic for women with HIV\n* \\> = 18 years old, with an HIV diagnosis\n* Pregnant or postnatal\n* Reside in South Florida\n* Able to communicate at the 6th grade level in English, Spanish or Haitian Creole.\n\nExclusion Criteria:\n\n* Under 18\n* Not able to read\u002Fwrite English, Spanish or Haitian Creole at the 6th grade level",{"count":371,"type":21},15,[74],"The purpose of BRIDGES (BReast and Infant feeding Doulas to address Gaps in Education and Support) is to develop, test and disseminate an HIV Doula education and support program to improve maternal\u002Fchild health outcomes and reduce perinatal transmission.",[375],"Pregnant HIV Positive Women",[377,378,201],"Doula","Infant Feeding","2026-06-17",{"date":202,"type":32},{"date":382,"type":21},"2026-09",{"date":384,"type":21},"2027-09",{"name":38,"class":39},{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":48,"minAge":18,"maxAge":393,"enrollmentInfo":394,"targetDuration":4,"studyType":22,"phases":396,"briefSummary":397,"conditions":398,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":400,"startDateStruct":401,"completionDateStruct":403,"leadSponsor":405,"locationsCount":40},"100560515","physiologic-effects-of-nasal-high-flow-on-exercise-tolerance-in-copd-100560515","NCT06578156","Physiologic Effects of Nasal High Flow on Exercise Tolerance in COPD","Physiologic Effects of Nasal High Flow on Exercise Tolerance in Chronic Obstructive Pulmonary Disease (COPD)","Inclusion Criteria:\n\n* Able to consent\n* Age 18 years or older\n* Diagnosis of COPD\n* Ability to ambulate without assistance\n* Use of low-flow nasal cannula ≤ 4 L\u002Fmin or no supplemental oxygen (O2) at all\n\nExclusion Criteria:\n\n* Pregnancy\n* Being on bedrest\n* Inability to consent or cooperate with the study\n* Using of \\> 4 L\u002Fmin of supplemental O2 or requiring non-invasive ventilation during the daytime\n* Hemodynamic instability (resting heart rate \\> 130\u002Fminute, systolic blood pressure of ≤ 90 mmHg or ≥ 180 mmHg)\n* Metal implants in the thoracic regions (pacemakers, Automatic Implantable Cardioverter Defibrillator (AICD), plates, screws, rods, and disc replacements)","100 Years",{"count":395,"type":21},45,[74],"This study aims to assess whether to describe the effects of the administration of nasal high flow (NHF) at 70 liters per minute (L\u002Fmin) in a 6-Minute Walk Test (6-MWT) among Chronic Obstructive Pulmonary Disease (COPD) patients and to characterize the association between self-reported dyspnea with and without NHF at 70 L\u002Fmin following a 6-MWT.",[399],"COPD",{"date":247,"type":32},{"date":402,"type":32},"2024-12-12",{"date":404,"type":21},"2027-12-31",{"name":38,"class":39},{"id":407,"slug":408,"hasResults":12,"nctId":409,"briefTitle":410,"officialTitle":411,"acronym":4,"eligibilityCriteria":412,"healthyVolunteers":69,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":413,"targetDuration":4,"studyType":22,"phases":415,"briefSummary":416,"conditions":417,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":379,"lastUpdatePostDateStruct":419,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":40},"100549339","joining-under-connected-networks-to-optimize-salud-health-juntos-100549339","NCT06432725","Joining Under-connected Networks to Optimize \"Salud\" (Health) (\"JUNTOS\")","Enhancing HIV Prevention and Treatment Referral and Engagement Among Latino Men Who Have Sex With Men (MSM): A Pilot Hybrid Effectiveness-Implementation Trial of the JUNTOS Referral Network","Inclusion Criteria:\n\nHIV Test counselors:\n\n* 18 years of age or older\n* Certified as an HIV test counselor in Miami-Dade County or Broward County (at the time of enrollment)\n* Working or volunteering as an HIV test counselor in Miami-Dade County or Broward County and report testing 2 or more Latino MSM client per month (at the time of enrollment)\n* Plans to continue working or volunteering as an HIV test counselor in Miami-Dade County or Broward County for the next 6 months\n* Reports suboptimal fidelity to pre-exposure prophylaxis (PrEP) referral guidelines (\\\u003C90% fidelity) and\u002For self-reports an unmet need for HIV prevention\u002Ftreatment referral resources\n\nLatino MSM:\n\n* 18 years of age or older\n* Identifies as Latino\u002Fa\u002Fx or Hispanic\n* Identifies as a sexual minority man or reports being a man who has sex with men\n* Speaks English and\u002For Spanish\n* Received a diagnostic HIV test from an HIV test counselor participating in the study or completed a diagnostic HIV test with a counselor in the last 3 months\n* Lives in Miami-Dade County, Broward County, or Palm Beach County and anticipates living there for the next three months\n\nExclusion Criteria:\n\nHIV test counselors:\n\n* Unable to consent\n* Study personnel unable to verify HIV test counselor role in Miami-Dade County or Broward County (e.g., confirmation of where they work\u002Fvolunteer as HIV test counselor, location they state they provide services doesn't exist or does not provide HIV testing services)\n* Works as an HIV test counselor in an incarceration\u002Fprison setting (i.e., clients are prisoners)\n\nLatino MSM:\n\n* Unable to consent",{"count":414,"type":21},245,[74],"The objective of this study is to evaluate the JUNTOS Referral Network as an implementation strategy to enhance the reach of HIV-prevention and treatment services to Latino gay, bisexual, and other men who have sex with men (MSM).",[418],"Hiv",{"date":247,"type":32},{"date":421,"type":32},"2024-11-07",{"date":423,"type":21},"2027-03-31",{"name":38,"class":39},{"id":426,"slug":427,"hasResults":12,"nctId":428,"briefTitle":429,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":12,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":432,"targetDuration":4,"studyType":22,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":56,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":444,"startDateStruct":445,"completionDateStruct":447,"leadSponsor":449,"locationsCount":40},"100630376","phase-2-emapalumab-mda5-rapidly-progressive-interstitial-lung-disease-rp-ild-study-100630376","NCT07486869","Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study","Emapalumab for the Treatment of Anti-MDA5 Antibody Positive Rapidly Progressive Interstitial Lung Disease","Inclusion Criteria:\n\n* Progressive interstitial lung disease as determined by at least 2\u002F4 of the following:\n\n  1. worsening respiratory symptoms;\n  2. worsening or new oxygen requirement;\n  3. worsening disease on CT chest;\n  4. worsening Forced Vital Capacity (FVC1) or Diffusing Capacity for Carbon Monoxide (DLCO) on pulmonary function tests\n* MDA5 antibodies present\n* Elevated ferritin above the upper limit of normal (ULN)\n* Participant at least 18 years old\n\nExclusion Criteria:\n\n* Active, untreated bacterial, mycobacterial or fungal infection\n* Active herpes zoster infection\n* Currently requiring extracorporeal membrane oxygenation (ECMO)\n* Participant refusal to participate in the study\n* Pregnant women\n* Prisoners",{"count":135,"type":21},[24],"This is a proof of concept study to determine if Emapalumab appears effective for the treatment of anti-MDA5 antibody positive rapidly progressive interstitial lung disease (MDA5 RP-ILD). Emapalumab is a medication that is currently used for a severe problem with the immune system, called macrophage activation syndrome, and this disease shares some similar features with MDA5 RP-ILD.",[436,437,438,439,440,441,442],"Dermatomyositis","Dermatomyositis Sine Myositis","Dermatomyositis With Myopathy","Dermatomyositis With Respiratory Involvement","Dermatomyositis With Organ Involvement","Interstitial Lung Disease","Interstitial Lung Disease Due to Connective Tissue Disease (Disorder)","2026-06-16",{"date":313,"type":32},{"date":446,"type":21},"2026-07",{"date":448,"type":21},"2027-05",{"name":38,"class":39},{"id":451,"slug":452,"hasResults":12,"nctId":453,"briefTitle":454,"officialTitle":455,"acronym":4,"eligibilityCriteria":456,"healthyVolunteers":69,"sex":48,"minAge":18,"maxAge":168,"enrollmentInfo":457,"targetDuration":4,"studyType":22,"phases":458,"briefSummary":459,"conditions":460,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":462,"startDateStruct":463,"completionDateStruct":465,"leadSponsor":467,"locationsCount":40},"100617407","prehabilitation-protocol-for-head-and-neck-cancer-patients-100617407","NCT07318220","Prehabilitation Protocol for Head and Neck Cancer Patients","Optimizing Cancer Support Services Usage in Patients With Head and Neck Cancer During the Prehabilitation Period","Aim 2 Inclusion Criteria: Implement prehabilitation prescription protocol and evaluate the feasibility and acceptability of the prehabilitation prescription protocol in a sample of HNC patients.\n\n1. Age 18 to 80 years old\n2. Patients with a diagnosis of non-metastatic squamous cell carcinoma originating in the head and neck (oral cavity, oropharynx, hypopharynx, larynx, and nasopharynx).\n3. Patients with a plan for curative radiation therapy (RT) \u002F chemoradiation therapy (CRT) at SCCC\\* - \\*Patients who underwent surgery for the HNC are still eligible.\n4. Clearance for exercise by the medical team.\n5. Patients who do not have their first treatment scheduled within 3 weeks at the time of recruitment.\n6. An English or Spanish speaker.\n\nAim 2 Exclusion Criteria:\n\n1. A patient with a metastatic cancer.\n2. A patient who cannot complete the baseline assessment and\u002For start prehabilitation by the initiation of RT\u002FCRT.\n3. Any contraindication for diet change or exercising as determined by a physician.\n\n   week for the prior month.\n4. A patient who is not an English or Spanish speaker.\n5. History of dementia or major psychiatric disease which would interfere with study.\n6. History of recent (≤1 yr) stroke, myocardial infarction, or congestive heart failure\n7. Eastern Cooperative Oncology Group (ECOG) equal to or higher than 2.",{"count":50,"type":21},[74],"The purpose of this research is to help researchers understand the barriers, supports, and preferences for prehabilitation. Prehabilitation in this study means head and neck cancer patients will receive nutritional counseling sessions and attend exercise programs before and during radiotherapy\u002Fchemoradiotherapy treatment.",[461],"Head and Neck Cancer",{"date":379,"type":32},{"date":464,"type":32},"2026-05-01",{"date":466,"type":21},"2027-08-30",{"name":38,"class":39},{"id":469,"slug":470,"hasResults":12,"nctId":471,"briefTitle":472,"officialTitle":473,"acronym":4,"eligibilityCriteria":474,"healthyVolunteers":12,"sex":48,"minAge":475,"maxAge":4,"enrollmentInfo":476,"targetDuration":4,"studyType":22,"phases":478,"briefSummary":479,"conditions":480,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":443,"lastUpdatePostDateStruct":482,"startDateStruct":483,"completionDateStruct":485,"leadSponsor":487,"locationsCount":40},"100587774","phase-2-adjuvant-quisinostat-in-high-risk-uveal-melanoma-100587774","NCT06932757","Adjuvant Quisinostat in High-Risk Uveal Melanoma","Phase 2 Trial of Adjuvant Quisinostat in High-Risk Uveal Melanoma","Inclusion Criteria:\n\n1. Primary diagnosis of uveal melanoma (UM) with a lesion of at least 12 mm in largest basal diameter (LBD) as clinically determined by the treating Investigator. Cytologic determination of diagnosis is not required. Size is based on clinical assessment (e.g., by ultrasound or direct ophthalmoscopy) prior to enucleation or radiation therapy.\n2. Definitive therapy of the primary UM must have been completed within 183 days of initiating protocol therapy.\n3. High-risk (class 2) UM as determined by gene expression profiling (GEP; DecisionDx-UM, Castle Biosciences Inc., Friendswood, TX).\n4. No evidence of metastatic disease.\n5. Patients aged \\>18 years.\n6. Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n7. Life expectancy of greater than 3 months.\n8. Ability to swallow and retain orally administered medication and no clinically significant gastrointestinal abnormalities that may alter absorption, such as malabsorption syndrome or major resection of the stomach or bowels.\n9. Adequate organ and marrow function as defined by the local institutional lab and treating physician.\n10. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until 6 months after completion of quisinostat administration. Women of childbearing potential must have a negative urine or serum pregnancy test within 14 days prior to study entry.\n11. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Additional malignancy that is progressing or requires active treatment. Exceptions include the following cancers: basal cell carcinoma or squamous cell carcinoma of the skin that has undergone potentially curative therapy, in situ cervical cancer, ductal carcinoma in situ (DCIS), incidentally discovered asymptomatic thyroid cancer, elevated levels of prostate-specific antigen (PSA) stable on hormonal therapy with no otherwise detectable disease, and a previous diagnosis of malignancy that has shown no evidence of disease progression for 2 years or longer.\n2. Any major surgery or extensive radiotherapy except that which is required for definitive treatment of primary UM.\n3. Previous adjuvant treatment for UM after definitive primary tumor therapy.\n4. History of prior Histone Deacetylase (HDAC) inhibitor use.\n5. Patients that cannot be taken off medications that are potent inhibitors of cytochrome (CYP) 3a4\u002FA5 (CYP3a4\u002FA5) and CYP2C9. Inclusion of these patients and of patients on warfarin will require discussion and approval by the Sponsor-Investigator prior to enrollment.\n6. Use of other investigational drugs within 28 days or five half-lives, whichever is shorter, with a minimum of 14 days from the last dose preceding the first dose of study treatment and during the study.\n7. Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to quisinostat.\n8. A QT interval corrected for heart rate using the Bazett's formula (QTcB) ≥ 480 msec or history of long QT syndrome.\n9. Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection except for patients with cleared HBV and HCV infection demonstrated by undetectable viral levels by polymerase chain reaction (PCR). HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with quisinostat.\n10. Patients with a cardiac ejection fraction outside of the normal range as defined by institutional standards or with a history of clinically significant cardiac arrhythmia as determined by a cardiologist.\n11. Uncontrolled intercurrent illness including but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, New York Heart Association (NYHA) Classifications 2-4, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements.\n12. History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or that makes participation in the trial to be not in the best interest of the patient in the opinion of the treating Investigator.\n13. Known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.\n14. Impaired decision-making capacity.","19 Years",{"count":477,"type":21},63,[24],"The purpose of this study is to see if giving participants quisinostat will prevent participants' uveal melanoma tumor from spreading. The researchers want to find out the effects that quisinostat has on participants' condition.",[481],"Uveal Melanoma",{"date":313,"type":32},{"date":484,"type":32},"2025-05-27",{"date":486,"type":21},"2030-05-27",{"name":38,"class":39},{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":238,"enrollmentInfo":495,"targetDuration":4,"studyType":22,"phases":496,"briefSummary":497,"conditions":498,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":501,"startDateStruct":502,"completionDateStruct":504,"leadSponsor":506,"locationsCount":40},"100577337","phase-1-botox-for-chronic-pelvic-pain-100577337","NCT06796985","Botox for Chronic Pelvic Pain","High-Density Surface Electromyography Guided Precision Botulinum Neurotoxin Injections to Manage Chronic Pelvic Floor Pain","Inclusion Criteria:\n\n1. Females between 18 and 75 years of age\n2. Clinical diagnosis of chronic pelvic pain\n3. Complaints of pain, pressure, or discomfort in the bladder and\u002For pelvic area for the past 6 months or more, associated with lower urinary tract symptoms (such as frequency of urination), in the absence of other explanation of the symptoms (e.g., UTI) \\*\n4. Myofascial pain diagnosed with palpable bands or nodules of contracted muscle fibers\n5. Pelvic muscle tenderness by assessment of pelvic floor muscles on digital pelvic examination\n6. No botulinum neurotoxin pelvic floor muscle injection treatment within 6 months prior to recruitment\n7. Able to provide informed consent\n\nExclusion Criteria:\n\n1. Males\n2. Women \\\u003C 18 and \\> 76 years of age\n3. History of pelvic malignancy and sexual transmitted diseases that is currently not in remission\n4. Bleeding disorder such as coagulopathy\n5. Hypersensitivity to botulinum neurotoxin\n6. Received botulinum neurotoxin pelvic floor muscle injection within 6 months prior to recruitment\n7. History of neurological disorders, such as spinal cord injury, multiple sclerosis, amyotrophic lateral sclerosis or myasthenia gravis\n8. Pregnancy, breast feeding or planning to get pregnant within one year after the last botulinum neurotoxin injection.",{"count":146,"type":21},[287],"The purpose of this research study is to find out if precise, targeted injection of botulinum neurotoxin (commonly known as Botox) provides better relief of pelvic floor hypertonicity and pain than the standard method being used. The researchers want to better understand the effects (good and bad) of targeted botulinum neurotoxin injections in women with pelvic floor disorders.",[499],"Pelvic Floor Disorders","2026-06-15",{"date":379,"type":32},{"date":503,"type":32},"2025-02-24",{"date":505,"type":21},"2027-03-22",{"name":38,"class":39},{"id":508,"slug":509,"hasResults":12,"nctId":510,"briefTitle":511,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":12,"sex":514,"minAge":18,"maxAge":515,"enrollmentInfo":516,"targetDuration":4,"studyType":22,"phases":518,"briefSummary":519,"conditions":520,"keywords":523,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":500,"lastUpdatePostDateStruct":526,"startDateStruct":527,"completionDateStruct":529,"leadSponsor":530,"locationsCount":40},"100512866","reset-for-the-treatment-of-stimulant-use-in-hiv-clinics-care-optimization-supporting-treatment-adherence-costa-100512866","NCT05958017","reSET for the Treatment of Stimulant Use in HIV Clinics: Care Optimization Supporting Treatment Adherence (COSTA)","COSTA","Inclusion Criteria:\n\n1. Assigned male sex at birth and has not undergone any transgender hormonal treatment\n2. Reports having had sex with a male in the past 12 months\n3. Age 18 or older\n4. Is affiliated with a study referral source (e.g., AHF clinic, registry, other healthcare program or clinic) or resides in a city or county where a participating healthcare center or health program is located\n5. Screens positive for mild, moderate or severe stimulant use disorder in the last 12 months using the MINI\n6. Reports that he is not currently in drug treatment\n7. Is living with HIV\n8. Reports having an active antiretroviral prescription\n9. Have access to a smartphone or tablet with stable internet at least twice a week and can download applications to the smartphone or tablet\n10. Able to understand English\n11. Consents to participation in the study\n12. Provides sufficient locator information\n13. Identifies as non-Hispanic White, non-Hispanic Black\u002FAfrican American or Latinx\u002FHispanic\n14. Has been in stable housing for the past 3 months and intends to remain housed for the next 15 months\n\nExclusion Criteria:\n\n1. Patient appears to have diminished capacity to consent either because of cognitive impairment or severe psychiatric symptoms (e.g., mania, psychosis).\n2. Persons that meet criteria for prisoner status will be excluded at baseline.\n3. Patients who screen positive for moderate to severe opioid use disorder will be excluded from the study because effective pharmacological agents exist for the treatment of this disorder. These patients will be referred to community-based programs that provide specialized treatment for this disorder.\n4. Participants will be excluded prior to randomization, if they do not complete at baseline the Time-Line Follow-Back or the laboratory visit.","MALE","90 Years",{"count":517,"type":21},260,[74],"The purpose of this study is to find out if reSET, an FDA authorized mobile therapeutic, is effective in treating stimulant use disorder and helping keep HIV viral load suppression stable among men who have sex with men who are living with HIV and have a stimulant use disorder.",[521,522],"Stimulant Use Disorder","People Living With HIV",[524,525],"Substance use","Adherence to Anti-Retroviral Therapy",{"date":379,"type":32},{"date":528,"type":32},"2025-03-04",{"date":319,"type":21},{"name":38,"class":39},{"id":532,"slug":533,"hasResults":12,"nctId":534,"briefTitle":535,"officialTitle":536,"acronym":537,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":514,"minAge":18,"maxAge":4,"enrollmentInfo":539,"targetDuration":4,"studyType":22,"phases":541,"briefSummary":542,"conditions":543,"keywords":547,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":549,"lastUpdatePostDateStruct":550,"startDateStruct":551,"completionDateStruct":553,"leadSponsor":555,"locationsCount":40},"100546235","phase-2-psma-directed-para-aortic-radiation-therapy-for-oligorecurrent-prostate-cancer-100546235","NCT06392295","PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer","A Phase II Trial of PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer - The OCEAN Trial","OCEAN","Inclusion Criteria:\n\n1. Histologically proven prostate adenocarcinoma\n2. Male, ≥ 18 years old\n3. Oligorecurrent disease limited to the sub-diaphragmatic region with or without pelvic lymph nodes\n\n   * a. No more than a total of 5 lesions on PSMA PET\u002FCT scan (each lesion defined as positive with standardized uptake value (SUV) \\> liver uptake and CT scan correlate)\n   * b. No disease outside of the pelvic and sub-diaphragmatic para-aortic lymph nodes\n   * c. At least one lesion in the sub-diaphragmatic pelvic or para-aortic lymph nodes\n   * d. Non-bulky nodal disease (ie, tumor \\\u003C5 cm)\n4. Prior pelvic radiation with disease response\n\n   * a. Definitive radiation therapy to the prostate with or without treatment of the pelvic lymph nodes and\u002For\n   * b. Salvage or adjuvant radiation therapy to the prostate bed following prostatectomy with or without treatment of the pelvic lymph nodes\n5. Hormone-sensitive prostate cancer\n6. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2\n7. Ability to understand the investigational nature, potential risks and benefits of the research study, and willingness to sign the written informed consent and HIPAA document(s)\n8. Willingness to fill out quality of life and psychosocial forms\n9. Willingness to participate in our institution's Prostate Cancer Database Protocol (ID# 20090767)\n\nExclusion Criteria:\n\n1. No pathological diagnosis of prostate adenocarcinoma\n2. Patient has more than 5 sites of metastatic disease\n3. Patient has history of bone and\u002For visceral metastasis\n4. No evidence of disease in the para-aortic or pelvic lymph nodes\n5. No staging with PSMA PET\u002FCT scan\n6. History of prior radiation therapy outside the pelvis for prostate cancer\n7. Bulky nodal disease \\>5 cm in tumor size\n8. Androgen deprivation therapy (ADT) or chemotherapy in the three months prior to staging PSMA PET\u002FCT scan (suggesting oligoprogressive disease, rather than true oligorecurrent disease) or at time of study enrollment\n9. Suspicious radiologic evidence of disease in the prostate on staging PSMA PET\u002FCT scan without confirmatory negative prostate biopsy\n10. Implanted hardware which limits treatment planning or delivery (determined by treating physician)\n11. Castration-resistant prostate cancer (history of rising PSA with serum testosterone level \\\u003C50 ng\u002FdL)\n12. Patients with ECOG performance status \\> 2\n13. History of inflammatory bowel disease\n14. History of malignancy other than prostate cancer except for non-melanoma skin cancer\n15. Patients unable to consent or are prisoners\n16. Unwilling to fill out quality of life and psychosocial forms\n17. Participants with impaired decision-making capacity",{"count":540,"type":21},34,[24],"The purpose of this prostate cancer research study is to learn about:\n\n1. Improving control of prostate cancer using radiation therapy, delivered to the para-aortic and pelvic lymph nodes, in addition to systemic androgen suppression therapy;\n2. Preserving quality of life after radiation therapy;\n3. Leveraging imaging results from prostate-specific membrane antigen (PSMA) positron emission tomography (PET)\u002Fcomputed tomography (CT) scans to evaluate and manage disease progression.",[544,545,546],"Prostate Cancer","Prostate Adenocarcinoma","Hormone Sensitive Prostate Cancer",[548],"Oligorecurrent Disease","2026-06-12",{"date":443,"type":32},{"date":552,"type":32},"2024-07-03",{"date":554,"type":21},"2029-08-01",{"name":38,"class":39},{"id":557,"slug":558,"hasResults":12,"nctId":559,"briefTitle":560,"officialTitle":561,"acronym":562,"eligibilityCriteria":563,"healthyVolunteers":12,"sex":48,"minAge":18,"maxAge":4,"enrollmentInfo":564,"targetDuration":4,"studyType":566,"phases":4,"briefSummary":567,"conditions":568,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":573,"lastUpdatePostDateStruct":574,"startDateStruct":575,"completionDateStruct":577,"leadSponsor":579,"locationsCount":580},"100323309","clinical-procedures-to-support-research-in-als-100323309","NCT03489278","Clinical Procedures to Support Research in ALS","Clinical Procedures to Support Research in ALS (CAPTURE-ALS)","CAPTURE-ALS","Inclusion Criteria:\n\n* Diagnosis of ALS or a related disorder (e.g. primary lateral sclerosis, progressive muscular atrophy).\n* Receiving care at a clinical center that uses Epic as its EHR.\n* Able and willing to provide informed consent (or informed consent obtainable from a designated proxy).\n\nExclusion Criteria:\n\n* Inability to understand English and\u002For Spanish",{"count":565,"type":21},1200,"OBSERVATIONAL","The purpose of the Clinical Procedures To Support Research (CAPTURE) study is to utilize information collected in the medical record to learn more about a disease called amyotrophic lateral sclerosis (ALS) and related disorders.",[569,570,571,572],"Amyotrophic Lateral Sclerosis","ALS-Frontotemporal Dementia","Primary Lateral Sclerosis","Progressive Muscular Atrophy","2026-06-11",{"date":500,"type":32},{"date":576,"type":32},"2018-02-15",{"date":578,"type":21},"2034-06",{"name":38,"class":39},11,""]